In vitro antimicrobial activity of ozenoxacin against methicillin-susceptible Staphylococcus aureus, methicillin-resistant S. aureus and Streptococcus pyogenes isolated from clinical cutaneous specimens in Japan.
Ozenoxacin, a novel non-fluorinated topical quinolone, was assessed for in vitro antimicrobial activity against each 50 isolates of methicillin-susceptible Staphylococcus aureus (MSSA), methicillin-resistant S. aureus (MRSA), and Streptococcus pyogenes according to the broth microdilution method recommended by the Clinical and Laboratory Standards Institute. The isolates used in this study were recovered from cutaneous specimens of Japanese adult and pediatric patients who visited hospitals in 2014. The MIC90s of ozenoxacin against MSSA, MRSA and S. pyogenes isolates from adult patients were ≤0.06, 4 and ≤0.06 μg/mL, respectively. The MIC90s of ozenoxacin against MSSA and S. pyogenes isolates from pediatric patients were equal to those against the adult isolates. On the other hand, the MIC90s of ozenoxacin against the pediatric MRSA isolates was 0.12 μg/mL, and was 32 times lower than that against the adult isolates. The antimicrobial activity of ozenoxacin against MSSA, MRSA and S. pyogenes was equal to or greater than those of 7 reference antimicrobial agents had been used for the treatment of skin infections. The MICs of ozenoxacin was highly correlated with those of nadifloxacin and levofloxacin in the 50 MRSA isolates (r(2) = 0.906 and 0.833, respectively). However, ozenoxacin kept the potent antimicrobial activity with the MIC ranging from 1 to 4 μg/mL even against MRSA low susceptible (MIC: >64 μg/mL) to nadifloxacin or levofloxacin. Ozenoxacin could represent the first-in-class non-fluorinated quinolone for the topical treatment of various superficial skin infections caused by MSSA, MRSA and S. pyogenes.
Drug Development Research Laboratories, Kyoto R&D Center, Maruho Co., Ltd., Japan. Electronic address: kanayama_din@mii.maruho.co.jp.
Shoji
S
Kanayama
Drug Development Research Laboratories, Kyoto R&D Center, Maruho Co., Ltd., Japan.
Fumiaki
F
Ikeda
Drug Development Research Laboratories, Kyoto R&D Center, Maruho Co., Ltd., Japan.
Kazuaki
K
Okamoto
Strategic Research Planning & Management Dept., Kyoto R&D Center, Maruho Co., Ltd., Japan.
Akiko
A
Nakajima
Drug Development Research Laboratories, Kyoto R&D Center, Maruho Co., Ltd., Japan.
Tatsumi
T
Matsumoto
Strategic Research Planning & Management Dept., Kyoto R&D Center, Maruho Co., Ltd., Japan.
Ritsuko
R
Ishii
Clinical Trial Testing Department, LSI Medience Co., Japan.
Ayako
A
Amano
Clinical Trial Testing Department, LSI Medience Co., Japan.
Kaoru
K
Matsuzaki
Clinical Trial Testing Department, LSI Medience Co., Japan.
Satoru
S
Matsumoto
D000279:Administration, Cutaneous; D000293:Adolescent; D000328:Adult; D000631:Aminopyridines / Q000008:administration & dosage / Q000494:pharmacology* / Q000627:therapeutic use; D000900:Anti-Bacterial Agents / Q000008:administration & dosage / Q000494:pharmacology* / Q000627:therapeutic use; D002648:Child; D005260:Female; D024841:Fluoroquinolones / Q000008:administration & dosage / Q000494:pharmacology / Q000627:therapeutic use; D006801:Humans; D007564:Japan; D064704:Levofloxacin / Q000627:therapeutic use; D008297:Male; D016106:Methicillin Resistance; D055624:Methicillin-Resistant Staphylococcus aureus / Q000187:drug effects* / Q000302:isolation & purification; D008826:Microbial Sensitivity Tests; D011807:Quinolizines / Q000008:administration & dosage / Q000494:pharmacology / Q000627:therapeutic use; D015363:Quinolones / Q000008:administration & dosage / Q000494:pharmacology* / Q000627:therapeutic use; D063465:Skin Cream / Q000008:administration & dosage / Q000627:therapeutic use; D017192:Skin Diseases, Bacterial / Q000188:drug therapy* / Q000382:microbiology; D013207:Staphylococcal Skin Infections / Q000188:drug therapy / Q000382:microbiology; D013297:Streptococcus pyogenes / Q000187:drug effects* / Q000302:isolation & purification
D000631:Aminopyridines; D000900:Anti-Bacterial Agents; D024841:Fluoroquinolones; D011807:Quinolizines; D015363:Quinolones; C062127:nadifloxacin; D064704:Levofloxacin; C000592413:ozenoxacin
MIC; MRSA; MSSA; Ozenoxacin; Streptococcus pyogenes; Superficial skin infections